IP Roundup: Veridex, Genomics USA, Steven Ebstein, Yale University | GenomeWeb

Veridex of Raritan, NJ, has received US Patent No. 8,183,353, "Breast cancer prognostics." A method is claimed for assessing the likelihood of a recurrence or metastasis of breast cancer in a patient diagnosed with or treated for breast cancer. The method involves the analysis of a gene expression profile that includes up to 56 genes. Arrays to capture and indicate the presence, absence, or degree of gene expression are also described as are kits that include reagents for conducting the gene expression analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions.

Ancestry.com is eyeing an expansion into genomic risk assessments, the Verge reports.